| 1 |
Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies [J]. Cancer Epidemiology, 2016, 40:39-46.
|
| 2 |
Yuval JB, Elazary R. The true incidence of gastric GIST: an update [J]. Obesity Surgery, 2018, 28(06): 1787.
|
| 3 |
TM. Coe, JK. Sicklick. Epidemiology of GIST[M]. Basel: Springer International Publishing, 2017.
|
| 4 |
Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies [J]. Hematol Oncol Clin North Am 2013, 27: 905-920.
|
| 5 |
SJ. Oiseth , MS. Aziz. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead [J]. 癌症转移与治疗（英文版）, 2017, 03(10): 250.
|
| 6 |
Tan Y, Garcia-Buitrago MT, Trent JC. The immune system and gastrointestinal stromal tumor [J]. Current Opinion in Oncology, 2015, 27(04): 338-342
|
| 7 |
Cameron S, Gieselmann M, Blaschke M, et al. Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST) [J]. Int J Clin Exp Pathol 2014; 7: 3563-3579.
|
| 8 |
Rusakiewicz S, Semeraro M, Sarabi M, et al.Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors [J]. Cancer Res 2013; 73: 3499-3510.
|
| 9 |
Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors [J]. Nature medicine, 2011, 17(06): 700-707.
|
| 10 |
Zhang JQ, Zeng S, Vitiello GA, et al. Macrophages and CD8＋ T cells mediate the anti-tumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors [J]. Cancer Immunology Research, 2018, 6(4): canimm. 0345.2017.
|
| 11 |
Núñez-Martín R, Cervera RC, Pulla MP. Gastrointestinal stromal tumour and second tumours: A literature review [J]. Medicina Clinica, 2017, 149(08):.
|
| 12 |
Seeber A, Perathoner A, Kocher F. Resistance in gastrointestinal stromal tumors [J]. memo - Magazine of European Medical Oncology, 2019(9574):.
|
| 13 |
Zhang JQ, Zeng S, Vitiello GA, et al. Macrophages and CD8+ T cells mediate the anti-tumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors [J]. 2018, 6(4):canimm.0345.2017.1
|
| 14 |
Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido [J]. Nat Med 2011, 17: 1094-1100.
|
| 15 |
Odorizzi PM, Pauken KE, Paley MA, et al., Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells [J]. Journal of Experimental Medicine, 2015, 212(07): 1125-1137.
|
| 16 |
Zhao R, Song Y, Wang Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway [J]. Cell Proliferation, 2019, 52: e12571.
|
| 17 |
Tan Y, Trent JC, Wilky BA, et al. Current status of immunotherapy for gastrointestinal stromal tumor [J]. Cancer Gene Therapy, 2017, 24(03):130-133.
|
| 18 |
Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, J Ostrowskiet al. PDL1 expression is an independent prognostic factor in localized GIST [J]. Oncoimmunology 2015, 4: e1002729.
|
| 19 |
Seifert AM, Zeng S, Zhang JQ, et al. PD-1/PD-L1 blockade enhances T cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors [J]. Clin Cancer Res, 2016,
|
| 20 |
Komita H, Koido S, Hayashi K, et al. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors [J]. Oncol Rep, 2015, 34: 2099-2105.
|
| 21 |
Saleiro D, Radecki SG, Platanias LC. Mesenchymal stromal cells and interferon α (IFNα) in cancer immunotherapy [J]. 2017, 05(NaN):S1039-S1043.
|
| 22 |
Chen LL, Chen X, Choi H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration [J]. Cancer Immunol Immunother 2012, 61: 1113-1124.
|
| 23 |
Pieter A. Boonstra JA, Gietema AJH.. Tyrosine kinase inhibitor sensitive PDGFR? Mutations in GIST. Two cases and review of the literature [J]. Oncotarget, 2017, 08(65):109836-109847.
|
| 24 |
Blanke CD, Rankin C, Demetri GD, et al., Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J]. Journal of Clinical Oncology, 2008. 26(04): 626-632.
|
| 25 |
Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial [J]. Jama Oncology, 2017, 03(05): 602.
|
| 26 |
Edris B, Willingham SB, Weiskopf K, et al. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci USA 2013, 110: 3501-3506.
|
| 27 |
Zhao W, Cao H. Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges [J]. Chinese Journal of Gastrointestinal Surgery, 2017, 20(09): 966-971.
|
| 28 |
Katz SC, Burga RA, Naheed S, et al. Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor [J]. J Transl Med, 2013, 11: 46.
|
| 29 |
Perez D, Hauswirth F, Jager D, et al. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors [J]. Int J Cancer 2011; 128: 2947-2952.
|
| 30 |
Ghadban T, Perez DR, Vashist YK, et al. Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors [J]. Eur J Surg Oncol 2014, 40: 1307-1312.
|